2014 EASO Position Statement on the Use of Anti-Obesity Drugs.
作者信息
Toplak Hermann, Woodward Euan, Yumuk Volkan, Oppert Jean-Michel, Halford Jason C G, Frühbeck Gema
机构信息
Department of Internal Medicine, Medical University, Graz, Austria.
出版信息
Obes Facts. 2015;8(3):166-74. doi: 10.1159/000430801. Epub 2015 May 1.
Abstract
摘要
相似文献
1
2014 EASO Position Statement on the Use of Anti-Obesity Drugs.2014年欧洲肥胖症研究学会关于抗肥胖药物使用的立场声明。
Obes Facts. 2015;8(3):166-74. doi: 10.1159/000430801. Epub 2015 May 1.
2
European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes.欧洲高血压学会肥胖问题工作组：肥胖药物与心血管结局
J Hypertens. 2011 Feb;29(2):189-93. doi: 10.1097/HJH.0b013e3283427c8b.
3
Obesity in Europe - does anybody care?欧洲的肥胖问题——有人在意吗？
Expert Opin Pharmacother. 2013 Jun;14(8):971-3. doi: 10.1517/14656566.2013.783016. Epub 2013 Mar 22.
4
Are we treating health or physical appearance when we prescribe drugs for obesity?当我们为治疗肥胖症而开药时，我们是在治疗健康问题还是关注身体外观？
Clin Pharmacol Ther. 2000 Mar;67(3):193-5. doi: 10.1067/mcp.2000.105242.
5
Drugs for the treatment of obesity.治疗肥胖症的药物。
JAMA. 2014 May 7;311(17):1807. doi: 10.1001/jama.2014.2104.
6
Drugs for the treatment of obesity--reply.治疗肥胖症的药物——回复
JAMA. 2014 May 7;311(17):1807. doi: 10.1001/jama.2014.2110.
7
[The search for drugs which can cure obesity].[寻找可治愈肥胖症的药物]
Vardfacket. 1997 Mar 10;21(3):35.
8
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.欧洲肥胖症的药物治疗：等待白乌鸫的到来。
Endocrinol Nutr. 2014 Dec;61(10):501-4. doi: 10.1016/j.endonu.2014.11.002.
9
Anti-obesity drugs: to be or not to be?抗肥胖药物：存在还是不存在？
Obes Rev. 2010 Dec;11(12):833-4. doi: 10.1111/j.1467-789X.2010.00828.x. Epub 2010 Nov 3.
10
[Current status of medical therapy for obesity and the potential of novel anti-obesity drug development].[肥胖症医学治疗的现状与新型抗肥胖药物研发的潜力]
Nihon Rinsho. 2013 Feb;71(2):324-8.
引用本文的文献
1
Development of the Italian clinical practice guideline on diagnosing and treating obesity in adults: scope and methodological aspects.意大利成人肥胖诊断与治疗临床实践指南的制定：范围及方法学方面
Eat Weight Disord. 2025 Jun 4;30(1):47. doi: 10.1007/s40519-025-01747-y.
2
A Guideline-Directed Approach to Obesity Treatment.一种基于指南的肥胖治疗方法。
Diabetes Spectr. 2024 Nov 15;37(4):281-295. doi: 10.2337/dsi24-0001. eCollection 2024 Fall.
3
Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study.约旦普通人群对使用胰高血糖素样肽-1受体激动剂进行减肥的认知、态度和行为；一项横断面研究。
PLoS One. 2024 Dec 5;19(12):e0314407. doi: 10.1371/journal.pone.0314407. eCollection 2024.
4
Waist-to-Height Ratio Cut-Off Points for Central Obesity in Individuals with Overweight Across Different Ethnic Groups in NHANES 2011-2018.2011-2018 年 NHANES 中不同族裔超重人群中心型肥胖的腰围身高比切点。
Nutrients. 2024 Nov 8;16(22):3838. doi: 10.3390/nu16223838.
5
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity.药物治疗作为肥胖症的减重手术辅助手段。
Drugs. 2024 Aug;84(8):933-952. doi: 10.1007/s40265-024-02029-0. Epub 2024 Jul 6.
6
Efficacy of multivitamin support following bariatric surgery in patients with obesity: a prospective observational study.肥胖症患者减肥手术后补充多种维生素的疗效：一项前瞻性观察研究。
Eat Weight Disord. 2024 May 7;29(1):34. doi: 10.1007/s40519-024-01655-7.
7
[Obesity and type 2 diabetes (Update 2023)].[肥胖与2型糖尿病（2023年更新版）]
Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):91-97. doi: 10.1007/s00508-023-02184-6. Epub 2023 Apr 20.
8
Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool.肥胖症药物：临床研究评价与推荐分级、评估、制定和评价工具。
Nutrients. 2023 Jan 24;15(3):606. doi: 10.3390/nu15030606.
9
European Association for the Study of Obesity Position Statement on Medical Nutrition Therapy for the Management of Overweight and Obesity in Adults Developed in Collaboration with the European Federation of the Associations of Dietitians.欧洲肥胖研究协会关于成人超重和肥胖管理的医学营养治疗立场声明，与欧洲营养师协会联合会合作制定。
Obes Facts. 2023;16(1):11-28. doi: 10.1159/000528083. Epub 2022 Dec 15.
10
Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control.肥胖相关高血压：发病机制、特征及控制因素。
Int J Mol Sci. 2022 Oct 14;23(20):12305. doi: 10.3390/ijms232012305.
本文引用的文献
1
Beyond BMI--phenotyping the obesities.超越体重指数——肥胖症的表型分析
Obes Facts. 2014;7(5):322-8. doi: 10.1159/000368783. Epub 2014 Oct 23.
2
Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.治疗糖尿病和肥胖的相互关系的疗法——GLP-1 和肥胖。
Expert Opin Pharmacother. 2014 Dec;15(17):2487-500. doi: 10.1517/14656566.2014.965678. Epub 2014 Sep 26.
3
American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action.美国临床内分泌医师协会和美国内分泌学会肥胖问题共识会议：建立全面行动的证据基础
Endocr Pract. 2014 Sep;20(9):956-76. doi: 10.4158/EP14279.CS.
4
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.现代肥胖药物治疗：权衡心血管风险与益处。
Clin Cardiol. 2014 Nov;37(11):693-9. doi: 10.1002/clc.22304. Epub 2014 Sep 15.
5
Medical and non-medical complications among children and adolescents with excessive body weight.超重儿童和青少年的医学及非医学并发症
BMC Pediatr. 2014 Sep 14;14:232. doi: 10.1186/1471-2431-14-232.
6
Medical treatment of obesity: the past, the present and the future.肥胖的医学治疗：过去、现在与未来。
Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):665-84. doi: 10.1016/j.bpg.2014.07.015. Epub 2014 Aug 8.
7
Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.服用氯卡色林期间的早期体重减轻、饮食和运动作为第52周体重减轻结果的预测指标。
Obesity (Silver Spring). 2014 Oct;22(10):2137-46. doi: 10.1002/oby.20841. Epub 2014 Jul 18.
8
Liraglutide in the treatment of obesity.利拉鲁肽治疗肥胖症
Expert Opin Biol Ther. 2014 Aug;14(8):1215-24. doi: 10.1517/14712598.2014.925870. Epub 2014 Jun 6.
9
Pharmacotherapy for obesity: novel agents and paradigms.肥胖症的药物治疗：新型药物与治疗模式。
Ther Adv Chronic Dis. 2014 May;5(3):135-48. doi: 10.1177/2040622314522848.
10
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.纳曲酮/安非他酮治疗肥胖的药物安全性评价。
Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28.
Zotero 插件